P Arenberger1, A Fialova1, S Gkalpakiotis1, A Pavlikova2, I Puzanov3, M Arenbergerova1. 1. Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic. 2. Institute for Laboratory Diagnostics, Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic. 3. Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract
BACKGROUND: Novel immunotherapy modalities significantly improve survival of patients with metastatic melanoma. However, CTLA-4-blocking monoclonal antibody ipilimumab is effective only in a small proportion of patients. Biomarkers for prediction of treatment response are indispensably needed. OBJECTIVE: To determine the utility of multimarker detection of circulating melanoma cells as prognostic and pharmacodynamic biomarker in patients with metastatic melanoma treated with ipilimumab. METHODS: Patients (n = 62) with metastatic melanoma in unresectable stage III or metastatic stage IV treated with ipilimumab were recruited prospectively. The values of four melanoma markers on circulating cells Melan-A, gp100, MAGE-3 and melanoma inhibitory antigen prior to the treatment and within the therapy were compared to the data collected at baseline - after the melanoma surgery. RESULTS: The immunotherapy pretreatment marker level was found to be prognostic of overall survival; lower levels were linked to longer survival time. Moreover, longitudinal follow-up of melanoma markers in patients treated with ipilimumab correlates with therapy response. A decline of marker levels by >30% at week 6 (in 83% of the responding subjects) to week 9 (in all responders) of ipilimumab administration was associated with response to therapy. Elevation of the tumour markers during the treatment precedes clinical progression and gives an early warning of treatment failure. CONCLUSION: Melanoma circulating cells hold potential as predictive and pharmacodynamic biomarker of immunotherapy.
BACKGROUND: Novel immunotherapy modalities significantly improve survival of patients with metastatic melanoma. However, CTLA-4-blocking monoclonal antibody ipilimumab is effective only in a small proportion of patients. Biomarkers for prediction of treatment response are indispensably needed. OBJECTIVE: To determine the utility of multimarker detection of circulating melanoma cells as prognostic and pharmacodynamic biomarker in patients with metastatic melanoma treated with ipilimumab. METHODS:Patients (n = 62) with metastatic melanoma in unresectable stage III or metastatic stage IV treated with ipilimumab were recruited prospectively. The values of four melanoma markers on circulating cells Melan-A, gp100, MAGE-3 and melanoma inhibitory antigen prior to the treatment and within the therapy were compared to the data collected at baseline - after the melanoma surgery. RESULTS: The immunotherapy pretreatment marker level was found to be prognostic of overall survival; lower levels were linked to longer survival time. Moreover, longitudinal follow-up of melanoma markers in patients treated with ipilimumab correlates with therapy response. A decline of marker levels by >30% at week 6 (in 83% of the responding subjects) to week 9 (in all responders) of ipilimumab administration was associated with response to therapy. Elevation of the tumour markers during the treatment precedes clinical progression and gives an early warning of treatment failure. CONCLUSION:Melanoma circulating cells hold potential as predictive and pharmacodynamic biomarker of immunotherapy.
Authors: Kadri Õunap; Kristiina Kurg; Liisi Võsa; Ülo Maiväli; Marina Teras; Anu Planken; Mart Ustav; Reet Kurg Journal: Oncol Lett Date: 2018-05-10 Impact factor: 2.967
Authors: Wouter Ouwerkerk; Mirjam van den Berg; Sanne van der Niet; Jacqueline Limpens; Rosalie M Luiten Journal: Melanoma Res Date: 2019-10 Impact factor: 3.599
Authors: Riccardo Marconcini; Francesco Spagnolo; Luigia Stefania Stucci; Simone Ribero; Elena Marra; Francesco De Rosa; Virginia Picasso; Lorenza Di Guardo; Carolina Cimminiello; Stefano Cavalieri; Laura Orgiano; Enrica Tanda; Laura Spano; Alfredo Falcone; Paola Queirolo Journal: Oncotarget Date: 2018-01-03